Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have earned an average rating of “Moderate Buy” from the sixteen research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $11.7692.

Several research firms have recently commented on CMPX. Wall Street Zen cut shares of Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Citigroup reissued a “market outperform” rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. Piper Sandler raised their price objective on shares of Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Stifel Nicolaus set a $6.00 price objective on Compass Therapeutics in a research report on Monday, June 1st. Finally, LADENBURG THALM/SH SH began coverage on Compass Therapeutics in a report on Wednesday, July 1st. They set a “buy” rating and a $5.00 target price on the stock.

Hedge Funds Weigh In On Compass Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CMPX. LPL Financial LLC grew its holdings in Compass Therapeutics by 4.7% in the fourth quarter. LPL Financial LLC now owns 44,470 shares of the company’s stock worth $239,000 after purchasing an additional 2,000 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of Compass Therapeutics by 20.6% during the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock valued at $44,000 after purchasing an additional 2,164 shares during the last quarter. Focus Partners Wealth lifted its holdings in shares of Compass Therapeutics by 16.2% during the third quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock valued at $56,000 after purchasing an additional 2,206 shares during the last quarter. Invesco Ltd. boosted its position in shares of Compass Therapeutics by 5.3% in the 4th quarter. Invesco Ltd. now owns 63,901 shares of the company’s stock worth $343,000 after purchasing an additional 3,245 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Compass Therapeutics by 1.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company’s stock worth $619,000 after purchasing an additional 3,329 shares in the last quarter. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Stock Performance

CMPX opened at $2.00 on Wednesday. Compass Therapeutics has a 52-week low of $1.61 and a 52-week high of $6.88. The stock has a market capitalization of $360.18 million, a PE ratio of -5.00 and a beta of 0.95. The stock’s 50 day moving average price is $2.21 and its 200-day moving average price is $3.15.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Research analysts forecast that Compass Therapeutics will post -0.47 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.